People

Daniel F. Hayes, MD, the clinical director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center in Ann Arbor, will begin a 1-year term as president of the American Society of Clinical Oncology (ASCO) at its 2016 Annual Meeting in Chicago, IL, on June 6. He has a long history of conducting clinical and translational breast cancer research related to drug development and the clinical utility of biomarkers. He has been principally responsible for the introduction and adoption of several circulating tumor markers, including CA15-3, which identifies the protein MUC1, and for the characterization of circulating tumor cells.

Paul A. Bunn Jr., MD, a professor of medicine and the James Dudley Endowed Professor of Lung Cancer at the University of Colorado (UC) School of Medicine in Aurora, will receive the Karnofsky Memorial Award on June 4 at the ASCO meeting. The award pays tribute to his outstanding contributions to cancer research, such as identifying novel diagnostics and treatment strategies for lung cancer, and to treatment, by striving to improve outcomes for patients with the disease. Currently, Bunn is the principal investigator of the SPORE in Lung Cancer grant at UC, which supports translational research.

Also at the ASCO meeting, William G. Kaelin Jr., MD, a professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School, and a senior physician at Brigham and Women's Hospital, all in Boston, MA, will receive the Science of Oncology Award on June 5. Kaelin studies the functions of proteins encoded by specific tumor-suppressor genes. He led fundamental studies on the VHL protein, work that was instrumental in the approval of five VEGF inhibitors for the treatment of metastatic renal cell carcinoma, as well as two mTOR inhibitors, which indirectly block VEGF.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.